Mithra Pharmaceuticals SA

ENXTBR:MITRA Stock Report

Market Cap: €14.9m

Mithra Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Mithra Pharmaceuticals's earnings have been declining at an average annual rate of -23.7%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been declining at an average rate of 12% per year.

Key information

-23.7%

Earnings growth rate

31.8%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate-12.0%
Return on equityn/a
Net Margin-432.1%
Next Earnings Update26 Sep 2024

Recent past performance updates

Recent updates

Not Many Are Piling Into Mithra Pharmaceuticals SA (EBR:MITRA) Stock Yet As It Plummets 26%

Apr 06
Not Many Are Piling Into Mithra Pharmaceuticals SA (EBR:MITRA) Stock Yet As It Plummets 26%

Revenues Working Against Mithra Pharmaceuticals SA's (EBR:MITRA) Share Price Following 39% Dive

Feb 07
Revenues Working Against Mithra Pharmaceuticals SA's (EBR:MITRA) Share Price Following 39% Dive

Party Time: Brokers Just Made Major Increases To Their Mithra Pharmaceuticals SA (EBR:MITRA) Earnings Forecasts

Nov 09
Party Time: Brokers Just Made Major Increases To Their Mithra Pharmaceuticals SA (EBR:MITRA) Earnings Forecasts

These Analysts Just Made A Huge Downgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) EPS Forecasts

Oct 05
These Analysts Just Made A Huge Downgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) EPS Forecasts

Take Care Before Diving Into The Deep End On Mithra Pharmaceuticals SA (EBR:MITRA)

May 23
Take Care Before Diving Into The Deep End On Mithra Pharmaceuticals SA (EBR:MITRA)

Bullish: Analysts Just Made A Huge Upgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) Forecasts

Aug 11
Bullish: Analysts Just Made A Huge Upgrade To Their Mithra Pharmaceuticals SA (EBR:MITRA) Forecasts

Growth Investors: Industry Analysts Just Upgraded Their Mithra Pharmaceuticals SA (EBR:MITRA) Revenue Forecasts By 21%

Mar 13
Growth Investors: Industry Analysts Just Upgraded Their Mithra Pharmaceuticals SA (EBR:MITRA) Revenue Forecasts By 21%

Mithra Pharmaceuticals (EBR:MITRA) Is Making Moderate Use Of Debt

Dec 22
Mithra Pharmaceuticals (EBR:MITRA) Is Making Moderate Use Of Debt

Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Nov 24
Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt

Jun 07
Here's Why Mithra Pharmaceuticals (EBR:MITRA) Can Afford Some Debt

When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?

May 10
When Will Mithra Pharmaceuticals SA (EBR:MITRA) Turn A Profit?

Is Mithra Pharmaceuticals SA's (EBR:MITRA) Shareholder Ownership Skewed Towards Insiders?

Mar 18
Is Mithra Pharmaceuticals SA's (EBR:MITRA) Shareholder Ownership Skewed Towards Insiders?

We're Not So Sure You Should Rely on Mithra Pharmaceuticals' (EBR:MITRA) Statutory Earnings

Feb 16
We're Not So Sure You Should Rely on Mithra Pharmaceuticals' (EBR:MITRA) Statutory Earnings

Analysts Expect Breakeven For Mithra Pharmaceuticals SA (EBR:MITRA) Before Long

Jan 21
Analysts Expect Breakeven For Mithra Pharmaceuticals SA (EBR:MITRA) Before Long

Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Nov 29
Some Mithra Pharmaceuticals SA (EBR:MITRA) Analysts Just Made A Major Cut To Next Year's Estimates

Revenue & Expenses Breakdown

How Mithra Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ENXTBR:MITRA Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2340-1742463
30 Sep 2351-1262166
30 Jun 2363-791769
31 Mar 2365-691766
31 Dec 2267-601764
30 Sep 2244-761670
30 Jun 2222-931676
31 Mar 2222-1051581
31 Dec 2123-1171485
30 Sep 2121-1151586
30 Jun 2119-1131687
31 Mar 2114-1031783
31 Dec 209-921778
30 Sep 2044-311771
30 Jun 2079291664
31 Mar 208811661
31 Dec 1997-271657
30 Sep 1984-541547
30 Jun 1971-821437
31 Mar 1964-551236
31 Dec 1858-281136
30 Sep 1846-411039
30 Jun 1833-531042
31 Mar 1833-461045
31 Dec 1732-381048
30 Sep 1726-371246
30 Jun 1720-361343
31 Mar 1721-361439
31 Dec 1622-351634
30 Sep 1621-291729
30 Jun 1620-231924
31 Mar 1620-161717
31 Dec 1520-10159
30 Sep 1519-9137
30 Jun 1518-8104
31 Mar 1519-5103
31 Dec 1419-3103
31 Dec 1318-281

Quality Earnings: MITRA is currently unprofitable.

Growing Profit Margin: MITRA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MITRA is unprofitable, and losses have increased over the past 5 years at a rate of 23.7% per year.

Accelerating Growth: Unable to compare MITRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MITRA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).


Return on Equity

High ROE: MITRA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.